Clinical efficacy analysis of preoperative neoadjuvant chemotherapy in patients with pulmonary adenocarcinoma during stage IIIA
Journal of Global Oncology Oct 20, 2019
Zhang T, et al. - In this retrospective analysis of 42 patients with stage IIIA lung adenocarcinoma who were admitted to the Cancer Hospital of Jilin Province from 2015 to 2017, researchers compared neoadjuvant chemotherapy with targeted therapy with respect to efficacy and safety, to ultimately define the best treatment mode of lung cancer in local progression period. The patients were treated with at least 2 cycles of neoadjuvant chemotherapy or at least 6 weeks of new adjuvant targeted therapy prior to surgery. The objective remission rate of newly assisted TKI therapy vs neoadjuvant chemotherapy was estimated to be 63.2 % and 36.8 %, respectively, in patients with EGFR sensitive mutations in stage IIIA. Findings revealed a good effect of neoadjuvant targeted therapy vs preoperative neoadjuvant chemotherapy in patients with pulmonary adenocarcinoma with EGFR mutation in stage IIIA. Continuing TKI treatment for 1 month post-surgical resection can be tried by patients with partial remission for the first treatment evaluation.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries